Influenza-A virus vaccine - Aviex Technologies
Alternative Names: AVX-201; PROPHYLACTIC PANDEMIC INFLUENZA VACCINE - AviexLatest Information Update: 13 Sep 2023
At a glance
- Originator Aviex Technologies
- Class Influenza A vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza A virus infections
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Influenza A virus infections (Prevention) in USA (PO) (Aviex Technologies pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Influenza-A-virus-infections(Prevention) in USA (PO)
- 02 Aug 2016 Preclinical trials in Influenza-A virus infections (Prevention) in USA (PO)